• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
From functions to mechanisms of the prototypic complement C5 antibody BB5.1.从原型补体C5抗体BB5.1的功能到作用机制
Immunology. 2020 Oct;161(2):81-82. doi: 10.1111/imm.13261.
2
Characterizing the original anti-C5 function-blocking antibody, BB5.1, for species specificity, mode of action and interactions with C5.鉴定原始抗 C5 功能阻断抗体 BB5.1 的种属特异性、作用模式及与 C5 的相互作用。
Immunology. 2020 Oct;161(2):103-113. doi: 10.1111/imm.13228. Epub 2020 Jul 13.
3
Eculizumab-C5 complexes express a C5a neoepitope in vivo: Consequences for interpretation of patient complement analyses.依库珠单抗 - C5复合物在体内表达C5a新表位：对患者补体分析解读的影响。
Mol Immunol. 2017 Sep;89:111-114. doi: 10.1016/j.molimm.2017.05.021. Epub 2017 Jun 10.
4
Current and future pharmacologic complement inhibitors.当前及未来的药理学补体抑制剂。
Hematol Oncol Clin North Am. 2015 Jun;29(3):561-82. doi: 10.1016/j.hoc.2015.01.009. Epub 2015 Apr 4.
5
[C5: eculizumab].[C5：依库珠单抗]
Brain Nerve. 2014 Oct;66(10):1191-9. doi: 10.11477/mf.1416200008.
6
Structural Basis for Eculizumab-Mediated Inhibition of the Complement Terminal Pathway.依库珠单抗介导的补体末端途径抑制的结构基础。
J Immunol. 2016 Jul 1;197(1):337-44. doi: 10.4049/jimmunol.1600280. Epub 2016 May 18.
7
Eculizumab treatment during pregnancy does not affect the complement system activity of the newborn.孕期使用依库珠单抗治疗不会影响新生儿的补体系统活性。
Immunobiology. 2015 Apr;220(4):452-9. doi: 10.1016/j.imbio.2014.11.003. Epub 2014 Nov 13.
8
Improving renal outcomes in chronic anemia: learning from paroxysmal nocturnal hemoglobinuria.改善慢性贫血的肾脏预后：从阵发性夜间血红蛋白尿中汲取经验。
Am J Hematol. 2010 Aug;85(8):551-2. doi: 10.1002/ajh.21800.
9
Incomplete inhibition by eculizumab: mechanistic evidence for residual C5 activity during strong complement activation.依库珠单抗的不完全抑制作用：强补体激活过程中残余C5活性的机制证据
Blood. 2017 Feb 23;129(8):970-980. doi: 10.1182/blood-2016-08-732800. Epub 2016 Dec 27.
10
[Eculizumab in paroxysmal nocturnal hemoglobinuria].[依库珠单抗治疗阵发性夜间血红蛋白尿]
Med Sci (Paris). 2009 Dec;25(12):1126-9. doi: 10.1051/medsci/200925121126.

本文引用的文献

1
Characterizing the original anti-C5 function-blocking antibody, BB5.1, for species specificity, mode of action and interactions with C5.鉴定原始抗 C5 功能阻断抗体 BB5.1 的种属特异性、作用模式及与 C5 的相互作用。
Immunology. 2020 Oct;161(2):103-113. doi: 10.1111/imm.13228. Epub 2020 Jul 13.
2
Complement, infection, and autoimmunity.补体、感染与自身免疫。
Curr Opin Rheumatol. 2019 Sep;31(5):532-541. doi: 10.1097/BOR.0000000000000633.
3
Development and characterization of novel anti-C5 monoclonal antibodies capable of inhibiting complement in multiple species.新型抗 C5 单克隆抗体的开发与鉴定，可在多种物种中抑制补体。
Immunology. 2019 Aug;157(4):283-295. doi: 10.1111/imm.13083. Epub 2019 Jun 17.
4
The essential role of complement in antibody-mediated resistance to Salmonella.补体在抗体介导的沙门氏菌抵抗中的重要作用。
Immunology. 2019 Jan;156(1):69-73. doi: 10.1111/imm.13000. Epub 2018 Oct 10.
5
Characterizing a pH-switch anti-C5 antibody as a tool for human and mouse complement C5 purification and cross-species inhibition of classical and reactive lysis.将一种 pH 开关型抗 C5 抗体鉴定为一种工具，用于人和小鼠补体 C5 的纯化和对经典途径及旁路途径的反应性溶解的交叉物种抑制。
Immunology. 2018 Nov;155(3):396-403. doi: 10.1111/imm.12982. Epub 2018 Jul 30.
6
C5a induces caspase-dependent apoptosis in brain vascular endothelial cells in experimental lupus.在实验性狼疮中，C5a可诱导脑血管内皮细胞发生半胱天冬酶依赖性凋亡。
Immunology. 2016 Aug;148(4):407-19. doi: 10.1111/imm.12619. Epub 2016 Jul 11.
7
Systemic and local anti-C5 therapy reduces the disease severity in experimental autoimmune uveoretinitis.系统性和局部抗 C5 治疗可降低实验性自身免疫性葡萄膜炎的疾病严重程度。
Clin Exp Immunol. 2010 Mar;159(3):303-14. doi: 10.1111/j.1365-2249.2009.04070.x. Epub 2009 Dec 4.
8
Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria.用于治疗阵发性夜间血红蛋白尿的补体抑制剂依库珠单抗的发现与研发。
Nat Biotechnol. 2007 Nov;25(11):1256-64. doi: 10.1038/nbt1344.
9
The membrane attack pathway of complement drives pathology in passively induced experimental autoimmune myasthenia gravis in mice.补体的膜攻击途径在被动诱导的小鼠实验性自身免疫性重症肌无力中引发病理变化。
Clin Exp Immunol. 2006 Nov;146(2):294-302. doi: 10.1111/j.1365-2249.2006.03205.x.
10
Generation of a monoclonal antibody to mouse C5 application in an ELISA assay for detection of anti-C5 antibodies.针对小鼠C5产生的单克隆抗体在用于检测抗C5抗体的ELISA检测中的应用。
Mol Cell Probes. 1987 Jun;1(2):141-9. doi: 10.1016/0890-8508(87)90022-3.

从原型补体C5抗体BB5.1的功能到作用机制

From functions to mechanisms of the prototypic complement C5 antibody BB5.1.

作者信息

Milling Simon

机构信息

Institute of Immunity, Infection, and Inflammation, University of Glasgow, Glasgow, UK.

出版信息

Immunology. 2020 Oct;161(2):81-82. doi: 10.1111/imm.13261.

DOI:10.1111/imm.13261
PMID:33460089
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7496775/
Abstract

Antibodies that bind complement components were first identified over 30 years ago. Investigations into their functions in animal models motivated clinical studies that have now generated licensed products and a strong pipeline of future therapeutics. Despite this, the mechanisms of action of one of the first effective C5-binding antibodies, BB5.1, were not known. Here, we report a new study that reveals these mechanisms, enabling new approaches for designing C5-binding molecules for therapeutic use.

摘要

30多年前首次发现了能结合补体成分的抗体。对其在动物模型中功能的研究推动了临床研究，目前已产生了获批产品和一系列强大的未来治疗药物。尽管如此，首个有效的C5结合抗体BB5.1的作用机制仍不清楚。在此，我们报告一项新研究，揭示了这些机制，为设计用于治疗的C5结合分子提供了新方法。